Madagascar
Tuberculosis profile
| High HIV burden |
Population  2012 22 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 10 (4.3–19) 46 (19–84)
Mortality (HIV+TB only) 0.28 (0.25–0.33) 1.2 (1.1–1.5)
Prevalence  (includes HIV+TB) 99 (50–160) 442 (222–735)
Incidence  (includes HIV+TB) 52 (43–62) 234 (193–280)
Incidence (HIV+TB only) 0.64 (0.53–0.77) 2.9 (2.4–3.4)
Case detection, all forms (%) 49 (41–60)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 17 206 (72) Relapse 1 519 (78)
Smear-negative 1 804 (8) Treatment after failure 148 (8)
Smear-unknown / not done 0 (0) Treatment after default 279 (14)
Extrapulmonary 4 964 (21) Other 0 (0)
Other 0 (0)      
Total new 23 974   Total retreatment 1 946  
           
Other (history unknown) 289        
Total new and relapse 25 493   Total cases notified 26 209  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.5    
Age < 15 419 287 1 423
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 83   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 81  
Retreatment 80  
TB/HIV 2012 Number (%)
TB patients with known HIV status 14 146 (54)
HIV-positive TB patients 19 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 18 (95)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.49 (0.13–1.3) 3.9 (0.48–13)
MDR-TB cases among notified pulmonary
TB cases
94 (26–240) 76 (9–260)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 7 (<1%) 63 (3%) 70
Laboratory-confirmed MDR-TB cases 7 3 10
Patients started on MDR-TB treatment     5
Financing TB control 2013
National TB programme budget (US$ millions) 4.8
% Funded domestically 15%
% Funded internationally 85%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-16 Data: www.who.int/tb/data